![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 08, 2014 8:27:12 AM
8:03 am Catalyst Pharma reports 'Positive' cardiac safety results of its Phase 3 product, Firdapse tablets; the study met the pre-specified primary endpoint (CPRX) : Co announced positive results from a study jointly funded with, and conducted by BioMarin Pharma (BMRN) to assess the cardiac safety of Firdapse tablets (amifampridine also known as 3,4-DAP). Firdapse is approved in the E.U., where it is marketed by BioMarin. Firdapse is also currently in Phase 3 development in the U.S. for Lambert-Eaton Myasthenic Syndrome (:LEMS) by Catalyst.
http://yhoo.it/1hvg7Ak
Recent CPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 09:00:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 03:17:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:00:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:00:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 02:41:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 04:22:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/31/2024 08:50:35 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 05/31/2024 08:47:26 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 05/31/2024 08:46:49 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 05/31/2024 08:43:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:43:02 PM
- Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE® • GlobeNewswire Inc. • 05/30/2024 05:41:21 PM
- Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024 • GlobeNewswire Inc. • 05/28/2024 12:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 09:28:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:54:04 PM
- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 08:16:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:06:47 PM
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024 • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day • GlobeNewswire Inc. • 03/28/2024 12:03:00 PM
- Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium • GlobeNewswire Inc. • 03/27/2024 12:03:00 PM
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) • GlobeNewswire Inc. • 03/13/2024 11:55:00 AM
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference • GlobeNewswire Inc. • 03/05/2024 01:03:00 PM
- Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/28/2024 11:03:23 PM
- Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE • GlobeNewswire Inc. • 02/27/2024 01:03:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM